Did the Fosamax osteoporosis drug actually harm people? Our pharmaceutical liability attorneys examine that question in these stories.
Big Pharma: Is Paying Big Fines More Profitable than Telling Doctors and Consumers the Truth in Marketing?
This week, Johnson & Johnson etched its name in the history books of another big pharma company that has been fined over billions of dollars due to a drug manufacturer practices of improper marketing and failure to warn. Johnson & Johnson pled guilty to claims stemming from allegations that the giant pharmaceutical company knowingly marketed [...]
On September 25, 2013, the California Supreme Court denied the generic Fosamax manufacturers petition for review thereby upholding the June 13, 2013 Court of Appeal decision allowing people injured by generic Fosamax to go forward in the Courts and hold the generic manufacturers responsible. In denying the generic manufacturers Petition, the Supreme Court let stand [...]
In a major victory for consumers who used the generic form of Fosamax, (Alendronate sodium) on June 13, 2013 the California Court of Appeal, Fourth Appellate District, Division Three ruled that people who used the generic Fosamax were not preempted by Federal law and the decision in PLIVA, Inc. v. Mensing (2011131 S.Ct. 2567 but [...]
Big Pharma paid doctors more than $1 billion in 2012 to act in various spokesperson capacities, for travel and meals, as well as research and royalties, which is significantly more than reported in 2011. According to a new data reported in the Financial Times, that figure only includes the 12 leading drug makers who actually [...]
Who is Responsible for J&J’s DePuy ASR, Pinnacle, Ethicon’s Gynecare, and Merck’s Vioxx and Fosamax?
Consumers injured by defective devices face an armada of attorneys as they seek to hold accountable device makers such as J&J’s hip implants DePuy ASR, DePuy Pinnacle, J&J’s transvaginal mesh product Ethicon, and Merck’s FOSAMAX that has left countless post menopausal women with atypical femur fractures. Currently there are over 10,000 pending cases in the [...]
Glynn v. Merck Sharp & Dohme Corp. (3:11-cv-05304, U.S. District Court, District of New Jersey) started trial in April 2013. Evidence was presented from internal documents and experts from both sides as to the benefits and risks of Fosamax. The jury was asked to decide if Fosamax was defective, whether Merck provided adequate warnings, and [...]
Medical Device Reporting for People Injured by Vaginal Mesh, Actos, Fosamax, and DePuy ASRs: What the Consumer Needs to Know
Manufacturers, user facilities and importers of medical devices are mandated to submit certain adverse events to the U.S. Food and Drug Administration [FDA]. Medical device reporting requires that manufacturers report to the FDA when they learn that one of their devices may have contributed to a death or serious injury. Consumers and health professionals can [...]
A new study published May 21, 2012 on line by the Archives of Internal Medicine said it found a link between bisphosphonate use (one of which is Fosamax) and atypical thigh fractures. Fosamax, Used to Treat Osteoporosis, Is Linked To Unusual Bone Fractures in The Femur Of 477 patients fifty years and older [...]
Merck, makers of VIOXX and FOSAMAX among other drugs, agreed to pay $950 million to settle criminal and civil claims that it illegally promoted the drug VIOXX. Merck will plead guilty to a misdemeanor offense and pay $321,636, 000 criminal fines. According to the Justice Department, Merck also entered into a civil settlement and will [...]
About 11% of women 55 years of age and older take drugs containing bisphosphonates (including Fosamax, Aclasta, Actonel, Altevia, and Boniva) to treat and prevent osteoporosis. This drug has been under increased scrutiny since a link was suspected between long term use and bone death (osteonecrosis) of the jaw and an increase in atypical femur [...]